Form 4: Nutanix Director Sells Shares Under 10b5-1 Plan

Nutanix Director Teresa Gayle Sheppard sold 3,500 shares of Class A Common Stock for approximately $267,691 under a pre-arranged 10b5-1 trading plan.

Summary

• Nutanix Director Teresa Gayle Sheppard reported the sale of 3,500 shares of Nutanix, Inc. Class A Common Stock.
• The transactions occurred on October 2, 2025, and were executed automatically under a Rule 10b5-1 trading plan established on July 3, 2025.
• The shares were sold in two separate transactions: 2,900 shares at a weighted average price of $76.4018 per share and 600 shares at a weighted average price of $76.8767 per share.
• Following these sales, Ms. Sheppard beneficially owns 22,400 shares of Class A Common Stock, which includes 3,646 unvested Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan, which typically has a neutral impact on sentiment as it is not indicative of new information or a change in management's view of the company's prospects.

Negatives

• A director sold 3,500 shares of company stock, which could be perceived as a lack of confidence, although mitigated by the 10b5-1 plan.

Future Outlook

NA

Industry Context

This is a routine insider transaction report (Form 4) and does not provide specific industry context or trends. Insider sales, especially those under a 10b5-1 plan, are common across industries for diversification or liquidity purposes.

Stakeholder Impact

• Shareholders: The sale by a director could be viewed with slight caution, though the pre-arranged 10b5-1 plan mitigates concerns about immediate negative implications for the company's stock performance.

Key Dates

Recommendation

The filing is a routine Form 4 reporting an insider sale executed under a Rule 10b5-1 trading plan. Such pre-scheduled sales are common for diversification or liquidity and are generally not indicative of a change in the company's fundamentals or management's outlook. Therefore, this specific filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation.

Keywords

Nutanix, NTNX, Insider Trading, Form 4, Director Sale, 10b5-1 Plan, Equity Sales